BioWorld

Aug. 29, 2008

View Archived Issues

Valeant Gets $125M Up Front from GSK in Epilepsy Deal

Valeant Pharmaceuticals International and GlaxoSmithKline plc said they are collaborating on the investigational drug retigabine for epilepsy, a deal that gives Valeant a $125 million up-front payment. (BioWorld Today) Read More

BDSI's Cancer Pain Patch on Pathway to Approval

Read More

Normal Cells May Contribute to Breast Cancer Metastases

Read More

Further Staff Cuts as Replidyne Reviews Strategic Alternatives

Read More

Holiday Notice

Read More

Clinic Roundup

Read More

Other News To Note

Read More